MASH

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH).

liver
Biotech

Madrigal pays Pfizer $50M for MASH drug with combo potential

Madrigal paid $50 million for a DGAT2i inhibitor that the biopharma intends to combine with its approved liver disease drug Rezdiffra.
James Waldron Jan 9, 2026 10:50am
obesity overweight weight loss weigh

MetaVia weighs in with 9% loss to enter the obesity ring

Jan 5, 2026 10:44am
person throwing away garbage or recycling

After $4.8B Amicus buy, BioMarin drops genetic disease asset

Dec 22, 2025 11:12am
next step ladder climb succeed win

Altimmune eyes phase 3 MASH trial as weight loss deepens

Dec 19, 2025 8:30am
liver

FDA qualifies 1st AI drug development tool in MASH

Dec 9, 2025 12:12pm
ESMO AstraZeneca

AstraZeneca drops MASH drug over disappointing data

Nov 6, 2025 5:21am